Stockreport

Prevail Therapeutics Provides Program Update on PR001 in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease

Prevail Therapeutics Inc.  (PRVL) 
Last prevail therapeutics inc. earnings: 11/12 09:30 am Check Earnings Report
PDF NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ: PRVL), a biotechnology company developing AAV-based gene therapies for patients with ne [Read more]